Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : European Medicines Agency Recommends Asthma Treatment Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 01:23pm CET

By Adam Clark

AstraZeneca PLC (AZN.LN) said Friday that the European Medicines Agency has recommended the marketing authorization of its benralizumab drug for asthma treatment.

The pharmaceutical company said the recommendation is based on phase 3 clinical trial data and is an important step towards providing a next-generation treatment for severe, uncontrolled asthma patients.

The positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The drug is also under regulatory review in the U.S., Japan and several other countries.

Shares are down 54 pence, or 1.1%, at 4908 pence at 1203 GMT.

Write to Adam Clark at [email protected]; @AdamDowJones

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
06:30p ASTRAZENECA : receives US FDA approval for Faslodex to treat advanced breast can..
11/16 ASTRAZENECA : Data on Eye Proteins Reported by Researchers at AstraZeneca (A pre..
11/16 ASTRAZENECA : New Pharmaceutical Research Data Have Been Reported by Researchers..
11/16 ASTRAZENECA : FDA approves Fasenra for severe eosinophilic asthma
11/16 ASTRAZENECA : shares up 1.2% after getting regulatory green light for asthma dru..
11/16 ASTRAZENECA : Fasenra (benralizumab) receives US FDA approval for severe eosinop..
11/16 ASTRAZENECA : First EU approval for fulvestrant in combination with a CDK4/6 inh..
11/16 ASTRAZENECA : s Fasenra scores US approval in severe asthma
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/15 ASTRAZENECA : FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment..
More news
News from SeekingAlpha
11:17a AstraZeneca in talks to settle Texas lawsuit over off-label Seroquel marketin..
07:42a AstraZeneca to present new late-stage data on cancer drugs at ESMO Asia
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 16, 2017
11/15 YOUR DAILY PHARMA SCOOP : Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA A..
Financials ($)
Sales 2017 21 797 M
EBIT 2017 5 886 M
Net income 2017 2 296 M
Debt 2017 12 460 M
Yield 2017 4,13%
P/E ratio 2017 33,28
P/E ratio 2018 27,92
EV / Sales 2017 4,40x
EV / Sales 2018 4,40x
Capitalization 83 533 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 68,1 $
Spread / Average Target 3,0%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA12.92%83 533
JOHNSON & JOHNSON20.74%373 077
NOVARTIS10.73%218 225
PFIZER8.87%211 963
ROCHE HOLDING LTD.-2.06%200 423
MERCK AND COMPANY-6.91%150 468